

Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations

Katarzyna Dudek

Universite Laval

Sam Paton

Universite Laval

Adeline Collignon

Universite Laval

Manon Lebel

Universite Laval <https://orcid.org/0000-0003-1649-1214>

Olivier Lavoie

Universite Laval

Jonathan Bouchard

Universite Laval

Fernanda Neutzling Kaufmann

Universite Laval

Laurence Dion-Albert

Universite Laval

Valerie Clavet-Fournier

Universite Laval

Luisa Bandeira Binder

Universite Laval

Claudia Manca

Universite Laval

Nicolas Flamand

Universite Laval

Manuel Guzman

University of Madrid

Matthew Campbell

Trinity College Dublin

Gustavo Turecki

Douglas Institute, Department of Psychiatry, McGill University <https://orcid.org/0000-0003-4075-2736>

Naguib Mechawar

McGill University <https://orcid.org/0000-0003-4960-756X>

Flavie Lavoie-Cardinal

Université Laval <https://orcid.org/0000-0002-4496-5088>

Cristoforo Silvestri

Université Laval

Vincenzo Di Marzo

Université Laval and Institute of Biomolecular Chemistry of the National Research Council, Naples

Caroline Menard (✉ caroline.menard@fmed.ulaval.ca)

Université Laval <https://orcid.org/0000-0001-8202-7378>

Article

Keywords: astrocyte end-feet, neurovasculature, stress adaptation, perivascular Cnr1, depression

Posted Date: June 2nd, 2023

DOI: <https://doi.org/10.21203/rs.3.rs-2978353/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: There is **NO** Competing Interest.

1 **Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-**
2 **brain barrier alterations.**

3

4 Katarzyna A Dudek¹, Sam E.J. Paton¹, Adeline Collignon¹, Manon Lebel¹, Olivier Lavoie¹,
5 Jonathan Bouchard¹, Fernanda Neutzling Kaufmann¹, Laurence Dion-Albert¹, Valerie Clavet-
6 Fournier¹, Luisa Bandeira Binder¹, Claudia Manca², Nicolas Flamand², Manuel Guzman³,
7 Matthew Campbell⁴, Gustavo Turecki⁵, Naguib Mechawar⁵, Flavie Lavoie-Cardinal¹, Cristoforo
8 Silvestri², Vincenzo Di Marzo⁶, Caroline Menard^{1*}

9

10

11 **Abstract**

12 **Blood-brain barrier (BBB) alterations contribute to stress vulnerability and development of**
13 **depressive behaviors. In contrast, neurovascular adaptations underlying stress resilience**
14 **remain unexplored. Here, we report that high expression of astrocytic cannabinoid receptor**
15 **1 (CB1) in the nucleus accumbens (NAc) shell, particularly in the endfeet ensheathing blood**
16 **vessels, is associated with resilience despite chronic social stress exposure. Viral-mediated**
17 **overexpression of *Cnr1* in astrocytes of the NAc shell has baseline anxiolytic effects and**
18 **dampened stress-induced anxiety- and depression-like behaviors. It also reduced astrocyte**
19 **inflammatory response and morphological changes following an immune challenge with the**
20 **cytokine interleukin-6, linked to stress susceptibility and mood disorders. At the preventive**
21 **and therapeutic level, physical exercise and antidepressant treatment increased perivascular**
22 **astrocytic *Cnr1* in mice. Loss of *CNRI* was confirmed in the NAc astrocytes of depressed**
23 **individuals. These findings suggest a role for the astrocytic endocannabinoid system in stress**
24 **responses and possibly, human depression, via BBB modulation.**

25 **Introduction**

26 Major depressive disorder (MDD) is a leading cause of disabilities worldwide, with one
27 out of five individuals affected throughout their lifetime¹⁻³. MDD's increasing global burden is
28 due to the low efficacy of current treatments, having only 30% success rate³. This highlights the
29 need for better understanding of underlying causal biological factors, not addressed with
30 traditional treatments. Chronic stress is the main environmental risk for MDD development, with
31 its social aspect contributing to mood disorder prevalence and suicide attempts in victims of
32 bullying⁴. We previously reported that both chronic social stress and MDD alter blood-brain
33 barrier (BBB) integrity⁵⁻⁷. The BBB is a dynamic frontier responsible for regulation of molecular
34 exchange between the periphery and the brain, critical for the maintenance of its homeostasis^{8,9}.
35 In mice, chronic social stress induces BBB disruption promoting depression-like behaviors,
36 highlighting a link between neurovascular health and stress vulnerability^{5-7,10}. Accordingly, mice
37 resilient to stress exhibit molecular adaptations favoring BBB integrity, possibly contributing to
38 proper coping strategies^{6,7}.

39 The endocannabinoid system (ECS) is a crucial regulator of stress responses, and its
40 disruption is associated with depressive behaviors in both clinical and preclinical studies¹¹⁻¹³.
41 Cannabinoid receptor 1 (CB1, encoded by *Cnr1*) is the main ECS effector in the brain and CB1
42 downstream signaling has been implicated in stress resilience^{12,14}. Astrocyte end-feet establish the
43 link between endothelial cells and neurons, enabling neurovascular communication, crucial to
44 BBB function¹⁵. Intriguingly, coverage of blood vessels by astrocyte end-feet interaction is
45 reduced in postmortem brain samples from individuals with MDD¹⁶. Function of CB1 on the
46 astrocyte membrane close to synaptic terminals has been widely investigated¹⁷ and a recent study
47 implicated mitochondrial CB1 in the regulation of glucose metabolism and behaviors¹⁸. However,
48 perivascular astrocytic CB1 remain understudied¹⁹ despite perfect positioning to modulate BBB
49 properties during stress exposure and in mood disorders, or other conditions like vascular and
50 neurodegenerative diseases, which are characterized by comorbidity with depressive symptoms
51 and BBB alterations¹.

52 To address this knowledge gap, we first evaluated astrocytic *Cnr1* expression in the
53 nucleus accumbens (NAc) and prefrontal cortex (PFC) of mice subjected to the chronic social
54 defeat stress paradigm (CSDS), a mouse model of depression²⁰, with loss of BBB integrity being
55 observed in these brain areas after chronic stress exposure^{5,7}. The NAc is a forebrain nucleus
56 playing key roles in reward and mood regulation while the PFC is involved in social behaviors,
57 executive function and decision making²¹. Next, viral-mediated functional experiments were
58 performed to manipulate expression of *Cnr1* in astrocytes and the impact thereof on anxiety- and
59 depression-like behaviors was assessed. Morphological analysis of perivascular astrocytic CB1
60 with super-resolution microscopy was combined with cell-specific transcriptomic analysis and *in*
61 *vitro* experiments to gain mechanistic insights on EC alterations underlying stress vulnerability vs
62 resilience. Prevention and treatment of mood disorders remain a major challenge in psychiatry.
63 Both physical exercise and positive antidepressant treatment response were associated with
64 increased NAc *Cnr1* expression in mice. Translational value was validated on postmortem brain
65 samples from individuals with MDD. This study is the first, to our knowledge, to link perivascular
66 EC signaling at astrocytic CB1 with stress resilience and mood disorders.

67

68


69 **Results**

70

71 **Increased astrocytic CB1 expression in the nucleus accumbens shell is associated with stress** 72 **resilience.**

73 CSDS induces a depression-like phenotype in a stress-susceptible (SS) subpopulation of
74 mice, mimicking MDD symptoms such as social avoidance, anhedonia, and anxiety²⁰. An
75 advantage of this paradigm is the generation of a subpopulation of animals with behaviors
76 comparable to unstressed controls (CTRL) and defined as resilient (RES) despite exposure to the
77 same stressor, allowing to investigate the biology underlying resilience along with stress
78 vulnerability. In the CSDS protocol, a male C57BL/6 mouse is subjected to 5 minutes of physical
79 bouts of social defeat by a CD-1 mouse aggressor for a duration of 10 days (**Fig.1A**). Behavioral
80 phenotype is assessed with the social interaction (SI) test performed 24 h after the last exposure to
81 social stress (**Fig.1A**). Mice that display social avoidance are considered SS as opposed to RES
82 animals with intact social behaviors (**Fig.1B, Supp.Fig.1A**). CSDS alters BBB integrity
83 promoting depression-like behaviors in SS mice but the mechanism underlying neurovascular
84 adaptations associated with stress resilience has yet to be determined. Considering its key role as
85 mediator of stress responses¹¹⁻¹³, we first evaluated individual differences in the ECS potentially
86 underlying stress responses in the NAc and PFC of SS vs RES males (**Fig.1C-D**). Indeed, we
87 showed that chronic stress alters BBB integrity in a sex-specific manner with the BBB being more
88 vulnerable in the female PFC⁷ vs NAc for males⁵. An unbiased transcriptional profiling of >40
89 ECS targets with a Taqman array revealed increased *Cnr1* gene expression in the NAc of stressed
90 males (**Fig.1D**), confirmed in RES only with more sensitive quantitative PCR analysis (**Fig.1C**).
91 Notably, *Cnr1* mRNA levels positively correlated with social interactions (**p=0.0002)
92 (**Fig.1C**). The changes were NAc specific, with no regulation observed in the PFC (**Fig 1D,**
93 **Supp.Fig.1B**) in line with intact BBB integrity⁵.

94 To identify whether RES-associated upregulation of NAc *Cnr1* is occurring in neurons or
95 astrocytes, immunofluorescence analysis was performed with the neuronal marker microtubule-
96 associated protein 2 (Map2) and S100 calcium-binding protein β (S100 β), which is enriched in
97 perivascular astrocytes²². In the NAc of male mice subjected to CSDS (**Supp.Fig.1C**) 71% of the
98 CB1 protein signal colocalized with neurons and 23% with astrocytes (**Fig.1F**). The NAc is
99 differentiated into at least two anatomically and functionally distinct regions^{23,24}. The NAc shell
100 has been implicated in the control of reward-seeking behavior by spatial/contextual information,
101 whereas the core appears to be involved in learning and action during goal-directed behavior^{25,26}.
102 The CB1 increase was observed in S100 β positive cells in the NAc shell of RES animals when
103 compared to CTRL and SS animals, and significantly correlated with social interactions in stressed
104 mice (**p=0.0012) (**Fig.1G-H**). CSDS led to an increase in CB1 in the NAc core neurons, but this
105 was not correlated with behavioral outcome (**Fig.1I-J**). Altogether, these findings suggest that
106 chronic stress resilience could be linked with NAc shell astrocyte specific CB1 upregulation.




109 **Figure 1. Increased astrocytic CB1 expression in the nucleus accumbens shell is associated with stress resilience.**
110 **A**, Experimental timeline of 10-day chronic social defeat stress (CSDS), social interaction (SI) and tissue collection.
111 **B**, Individual SI values (left) and representative heatmaps (right) of normalized time spent in the interaction zone
112 during SI test for male CSDS. **C**, Quantitative PCR revealed upregulation of *Cannabinoid receptor 1* (*Cnr1*) gene
113 expression in the nucleus accumbens (NAc) of stress resilient (RES) male mice when compared to unstressed control
114 (CTRL) and susceptible (SS) animals. **D**, Endocannabinoid system Taqman array revealed higher *Cnr1* gene
115 expression in stressed mice vs CTRL in the NAc but not prefrontal cortex (PFC), the range of color indicates individual
116 differences within a group with yellow indicating increased expression and blue decreased as compared to CTRL. **E**,
117 Individual SI values (left) and corner time (middle) with representative heatmaps (left). **F**, Cell type percentage
118 colocalizing with CB1 protein detected by immunofluorescence. **G**, Increased number of S100 β positive cells
119 expressing CB1-encoded protein in RES males as compared to SS and CTRL in the NAc shell, but not the NAc core
120 (**I**). Representative images of CB1, S100 β and Map2 immunohistochemistry in the NAc after social defeat stress in
121 shell (**H**) and core (**J**). Scale bars, 50 μ m. Data represent mean \pm s.e.m.; number of animals or subjects (n) is indicated
122 on graphs. One-way ANOVA or Brown-Forsythe ANOVA test followed by Holm-Šidák's or Tuckey's multiple
123 comparison test was applied. For n lower than 8, Kruskal-Wallis test followed by Dunn's multiple comparisons
124 evaluation was used; correlations were evaluated with Pearson's correlation coefficient; ***p \leq 0.001, **p \leq 0.01,
125 *p \leq 0.05.

126
127

128 **Astrocyte-specific increase of *Cnr1* expression in the NAc shell has anxiolytic effects.**

129 Involvement of NAc astrocytic CB1 in the regulation of anxiety- and depression-like
130 behaviors has yet to be investigated despite a key role for this brain area in emotion regulation and
131 mood disorders²¹. Thus, we designed an adeno-associated virus (AAV) vector driving *Cnr1*
132 expression in GFAP+ astrocytes that was first validated both *in vitro* and *in vivo* (**Fig.2A-B**,
133 **Supp.Fig.2A-D**). This approach allows upregulation of *Cnr1* expression in a region- and cell-
134 specific manner. Stereotactic injection of the AAV-GFAP-*Cnr1* in the NAc shell of naive male
135 mice increased *Cnr1* expression in GFAP positive astrocytes when compared to a control AAV-
136 GFAP-sham virus (**Fig.2A-B**). The NAc shell was targeted because stress resilience increases CB1
137 expression in this brain area (**Fig.1G-H**). Next, bilateral injection with either the AAV-GFAP-
138 *Cnr1* or AAV-GFAP-sham virus was performed in the NAc shell on other cohorts of mice and a
139 battery of behavioral tests was conducted 3 weeks later when viral expression is optimal (**Fig.2A**,
140 **B**). Overexpression of astrocytic *Cnr1* led to a reduction of anxiety-related behaviors as indicated
141 by increased time and number of entries in the center of the open field (OF) test arena when
142 compared to AAV-GFAP-sham-injected controls (*p=0.0186) (**Fig.2E**, **Supp.Fig.2G**). In the
143 elevated plus maze test (EPM), AAV-GFAP-*Cnr1*-injected mice did not spend more time in the
144 open arms but entered them more often than their sham-injected counterparts (**Fig.2D**,
145 **Supp.Fig.2F**). On the other hand, upregulation of *Cnr1* expression did not affect baseline social
146 behaviors in the SI test (**Fig.2C**, **Supp.Fig.2E**). As for the splash test (ST), mice injected with
147 AAV-GFAP-*Cnr1* in the NAc shell started grooming sooner vs the AAV-GFAP-sham controls
148 despite being exposed to a new environment, suggesting decreased anxiety (*p=0.0500) (**Fig.2F**).
149 Importantly, AAV-GFAP-*Cnr1* animals spending more time in the OF center also groomed
150 earlier, linking anxiolytic effects across different behavioral domains (*p=0.0383) (**Fig.2H**). As
151 for other depression-like behaviors, no effect was noted in the tail suspension test (TST) and forced
152 swim test (FST) (**Fig.2G**). However, low basal anxiety correlated with reduced anhedonia in the
153 sucrose preference test (SPT) and immobility in the FST (*p=0.0179) (**Fig.2H**). Taken together
154 these results suggest that an increase in astrocytic *Cnr1* in the NAc shell has anxiolytic effects,
155 even in unstressed animals. To our knowledge, this is the first evidence supporting a role for
156 astrocytic *Cnr1* role in regulating anxiety-like behaviors.

157



158
159 **Figure 2. Overexpression of astrocytic *Cnr1* in the nucleus accumbens shell has anxiolytic effects but does not**
160 **alter depression-like behaviors.** **A**, Experimental timeline of nucleus accumbens (NAc) bilateral injection of AAV-
161 GFAP-*Cnr1* or AAV-GFAP-sham viruses and following behavioral studies. **B**, Validation of AAV-GFAP-*Cnr1* or
162 AAV-GFAP-sham viruses with RNA scope confirmed upregulation of *Cannabinoid receptor 1* (*Cnr1*) mRNA levels
163 in AAV-GFAP-*Cnr1* infected astrocytes when compared to AAV-GFAP-sham-injected mice. RNA scope
164 representative images of AAV-GFAP-sham (left) and AAV-GFAP-*Cnr1* (right) viruses, Scale bars, 20 μ m. **C**, Viral
165 manipulation does not alter social behaviors as measured with the social interaction (SI) test. Individual SI values
166 (left) and representative heatmaps (right) of normalized time spent in the interaction zone during SI test. **D**, Bilateral
167 injection with AAV-GFAP-*Cnr1* has anxiolytic effect in the elevated plus maze (EPM) as animals enter more times
168 the open arms as compared to AAV-GFAP-sham injected animals (left). Representative heatmaps of time spent in the
169 open arms during EPM for animals injected with AAV-GFAP-*Cnr1* or AAV-GFAP-sham viruses (right). **E**, Similarly,


170 following bilateral injection with AAV-GFAP-*Cnr1* mice spend more time in the center of the arena open field (OF)
171 test when compared to AAV-GFAP-sham injected animals (left). Representative heatmaps of normalized time spent
172 in the center during OF test for animals injected with AAV-GFAP-*Cnr1* or AAV-GFAP-sham viruses (right). **F**,
173 Despite comparable latency of grooming behavior during the splash test (ST) (left), mice injected with the AAV-
174 GFAP-*Cnr1* virus starts grooming sooner in a new environment (right), indicating decreased anxiety. **G**, No difference
175 was observed in anhedonia (sucrose preference test, left) and other depression-like behaviors (tail suspension test,
176 TST, middle and forced swim test, FST, right) following viral manipulation. **H**, Intra-individual correlation of different
177 behavioral data points reveals correlations between anxiety and motivated behaviors. P values in the boxes refer to
178 the strength of the correlation between behaviors. Data represent mean \pm s.e.m.; number of animals or subjects (n) is
179 indicated on graphs. Two-tailed t-test or Mann-Whitney U test was applied; correlations were evaluated with Pearson's
180 correlation coefficient; * $p \leq 0.05$.

181

182

183 **Astrocyte-specific increase of *Cnr1* expression in the NAc shell promotes resilience following** 184 **chronic social stress exposure.**

185 *Cnr1*^{-/-}-deficient mice are highly sensitive to stress with increased mortality rate, altered
186 hypothalamic-pituitary-adrenal axis activation and exacerbated microglia responses in the PFC,
187 hippocampus, and amygdala²⁷. Transgenic mice lacking *Cnr1* on specific cortical neuronal
188 subpopulations are also more sensitive to the behavioral consequences of social stress exposure²⁸.
189 However, it is undetermined if *Cnr1* in the NAc astrocytes contributes to stress responses. Due to
190 higher expression of *Cnr1* observed in the NAc shell of resilient mice (**Fig.1G-H**), we explored
191 this hypothesis by injecting male mice with AAV-GFAP-*Cnr1* or the control AAV-GFAP-sham
192 virus, followed by the 10-day CSDS paradigm 3 weeks later and then a battery of behavioral tests
193 (**Fig.3A**). The detrimental effect of CSDS on social interactions was blunted in the AAV-GFAP-
194 *Cnr1* group. Indeed, AAV-GFAP-sham-injected animals displayed social avoidance with less time
195 spent in the interaction zone when the target is present when compared to unstressed AAV-GFAP-
196 sham controls (stress effect: * $p=0.0180$), a phenomenon not observed in AAV-GFAP-*Cnr1* mice
197 (**Fig.3B**, **Supp.Fig.3A**). Cell-specific expression of *Cnr1* in GFAP+ astrocytes was again
198 validated with RNA scope *in vivo* (**Fig.3C**). Increasing *Cnr1* expression in the NAc shell
199 astrocytes had anxiolytic effect not only in unstressed controls, confirming our previous
200 observations (**Fig.2**), but also in animals subjected to CSDS (**Fig.3D-E**, **Supp.Fig.3B-C**). Mice
201 injected with the AAV-GFAP-*Cnr1* in the NAc shell display decreased anxiety in EPM and OF
202 tests when compared to AAV-GFAP-sham animals (EPM: virus effect * $p=0.04$, OF: virus effect
203 ** $p=0.0089$) (**Fig.3D-E**). Similarly, AAV-GFAP-*Cnr1* injected mice exhibited decreased latency
204 to groom in ST test (virus effect * $p=0.0496$) (**Fig.3F**). Chronic stress induces grooming
205 perturbation in the ST due to a decrease in motivated behaviors and hedonic inclination²⁹ and
206 upregulation of astrocytic *Cnr1* in the NAc shell appears to protect against these behavioral
207 deficits (**Fig.3F**). AAV-GFAP-*Cnr1*-injected mice were characterized by overall increased
208 grooming behavior vs AAV-GFAP-sham animals following CSDS (virus effect: * $p=0.0145$)
209 (**Fig.3F**). As for other depression-like behaviors induced by 10-day CSDS, no difference was
210 observed for anhedonia or in the TST test (**Fig.3G**). However, higher mobility in the FST was
211 observed in mice expressing AAV-GFAP-*Cnr1* in the NAc shell astrocytes when compared to
212 animals injected with the AAV-GFAP-sham virus (virus effect: *** $p < 0.0001$) (**Fig.3G**). Overall,
213 these findings indicate that upregulation of *Cnr1* in the NAc shell astrocytes could represent a
214 positive biological adaptation contributing to resilience in the context of chronic social stress
215 exposure.



216
 217 **Figure 3. Overexpression of astrocytic *Cnr1* in the nucleus accumbens dampens anxiety- and depression-like**
 218 **behaviors induced by chronic social stress exposure.** **A**, Experimental timeline of nucleus accumbens (NAc)
 219 bilateral injection of AAV-GFAP-*Cnr1* or AAV-GFAP-sham viruses followed by 10-day chronic social defeat stress
 220 (CSDS) and behavioral studies. **B**, Bilateral AAV-GFAP-*Cnr1*, but not AAV-GFAP-sham injection in the NAc shell
 221 prevents social deficits induced by CSDS in males as depicted by individual social interaction (SI) test values (left),
 222 time in the interaction zone (middle) and representative heatmaps (right). **C**, RNA scope *in vivo* validation of AAV-
 223 GFAP-*Cnr1* expression in the NAc shell. **D**, Following bilateral injection with AAV-GFAP-*Cnr1*, mice spend more
 224 time in the elevated plus maze (EPM) open arms as compared to AAV-GFAP-sham injected animals (left).

225 Representative heatmaps of normalized time spent in the open arms during EPM test for animals injected with AAV-
226 GFAP-*Cnr1* or AAV-GFAP-sham viruses after CSDS (right). **E**, Decreased anxiety in animals treated with AAV-
227 GFAP-*Cnr1* as measured by increased time spent in the center during the open field (OF) test (left) as compared to
228 sham animals. Representative heatmaps of normalized time spent in OF arena for animals injected with AAV-GFAP-
229 *Cnr1* or AAV-GFAP-sham viruses following CSDS (right). **F**, Bilateral AAV-GFAP-*Cnr1* injection in the NAc shell
230 does not affect latency to start grooming (left) but increases grooming time in the splash test (ST) (right) as compared
231 to AAV-GFAP-sham suggesting positive effect on motivated behaviors. **G**, Bilateral AAV-GFAP-*Cnr1* injection in
232 the NAc shell does not affect anhedonia as evaluated by the sucrose preference test (left) but increases mobility in the
233 forced swim test (FST) (right) as compared to AAV-GFAP-sham. No effects of stress or viral manipulations were
234 noted for tail suspension (TST, middle). Data represent mean \pm s.e.m.; number of animals or subjects (n) is indicated
235 on graphs. Two-way ANOVA or Non-parametric Two-way ANOVA on Ranks followed by Holm-Šidák's or Wilcox
236 multiple comparison test was applied; ****p < 0.0001, *p \leq 0.05.

237


238

239 **Increased CB1 expression at the BBB interface in the NAc shell is associated with stress** 240 **resilience.**

241 Stress-induced BBB hyperpermeability mediated by loss of tight junction protein Cldn5
242 allowing passage of deleterious peripheral inflammatory mediators into the NAc is observed in
243 SS, but not RES, animals^{5,6} suggesting that protective neurovascular adaptations are present.
244 Endocannabinoids can modulate BBB permeability *in vitro*³⁰ and have beneficial effects in the
245 neuroinflammatory context of stroke³¹ or traumatic brain injury³², including via upregulation of
246 Cldn5 expression. Astrocytic CB1 receptors are well positioned to react to stress-associated
247 alterations in BBB endothelial cells. Thus, we evaluated if *Cldn5* loss in the male NAc affects
248 expression of *Cnr1*/CB1 in astrocytes using a doxycycline-inducible Cldn5-targeting shRNA
249 (AAV-shRNA-*Cldn5*)⁵. We chose this approach since *Cldn5*-deficient mice die within 10h of
250 birth³³ and it allows downregulation of *Cldn5* in a region- and cell-specific manner, with this tight
251 junction being expressed only in endothelial cells³⁴, leading to functional deficits with leakage of
252 circulating dyes or proteins into the brain^{5,35}. A cohort of mice was injected in the NAc shell with
253 either the AAV-shRNA-*Cldn5* or AAV-shRNA (control) virus (**Fig.4A**). Downregulation of
254 Cldn5 expression resulted in a compensatory increase in *Cnr1* and astrocytic end-feet-related
255 *aquaporin 4* (*Aqp4*) expression when compared to AAV-shRNA-injected animals (**Fig.4B**,
256 **Supp.Fig.4A-B**). *Aqp4* is a water channel involved in BBB transport but also polarization of
257 astrocyte end-feet¹⁶. Coverage of blood vessels by *Aqp4*+ astrocyte end-feet is reduced by 50% in
258 PFC samples from individuals with MDD¹⁶, supporting BBB alterations in this mood disorder.
259 Intriguingly, *Cnr1* expression is enriched in perivascular astrocytes³⁶. Morphological analysis of
260 confocal microscopy images performed with the Imaris software revealed that, in AAV-shRNA-
261 *Cldn5*-injected mice, high astrocyte *Aqp4*+ end-feet and endothelial CD31+ volume overlap is
262 correlated with elevated level of perivascular CB1 proteins, suggesting an involvement in
263 maintenance of BBB integrity (*p=0.0356) (**Fig.4C-D**).

264 Next, whether perivascular CB1 is linked or not to the resilient phenotype following CSDS
265 was evaluated. Exposure to 10-day chronic social stress decreased *Aqp4* in the NAc of SS but not
266 RES mice (**Fig.4E-G**). Importantly, a positive correlation between *Cldn5* and *Aqp4* expression
267 was noted in the male NAc following CSDS (***p=0.0001) (**Fig.4G**). Decreased *Aqp4* was
268 reported in the cortex and hippocampus of rodents exposed to chronic unpredictable stress³⁷ or
269 inflammation³⁸, but to our knowledge this is the first report of a similar effect of CSDS in the
270 NAc. *Aqp4*+ end-feet and endothelial CD31+ volume overlap is reduced in the SS group when
271 compared to unstressed controls and RES mice without reaching significance (**Fig.4H-J**,
272 **Supp.Fig.4C-E**). However, a decrease in vasculature volume, as measured with endothelial CD31

273 immunostaining, was noted in SS animals (**Fig.4K**), while in the NAc of RES mice CB1/CD31
274 colocalization was increased when compared to both SS and unstressed control group and
275 correlated with the level of social interactions (**p=0.0012) (**Fig.4L-M**). This observation was
276 confirmed using super-resolution microscopy (**Fig. 4N, Supp.Fig.4F**). Altogether, these results
277 suggest that astrocytic Cnr1 in the NAc dampens stress-induced neurovascular alterations
278 promoting resilience.



279

280 **Figure 4. High perivascular CB1 expression is associated with stress resilience following CSDS.** **A**, Experimental
 281 timeline of nucleus accumbens (NAc) bilateral virus injection of AAV-shRNA sham or AAV-shRNA-*Cldn5*,
 282 decreasing endothelial tight junction Claudin-5 (*Cldn5*) gene expression. **B**, Quantitative PCR revealed an increase in

283 mRNA levels of *Cannabinoid receptor 1* (*Cnr1*, left) and astrocytic end-feet marker *Aquaporin-4* (*Aqp4*, right) in
284 animals with BBB impairment induced by AAV-shRNA-*Cldn5* injection. **C**, Bilateral injection with AAV-shRNA-
285 *Cldn5* in absence of stress does not alter astrocytic end-feet coverage of NAc shell vessels (left). Astrocyte end-feet
286 expressing CB1 are more efficient in covering vessels in AAV-shRNA-*Cldn5* injected animals (right). **D**,
287 Representative images of astrocytic end-feet coverage of NAc shell vessels in AAV-shRNA (left) and AAV-shRNA-
288 *Cldn5*-injected animals (right). Scale bars 10 μ m. **E**, Experimental timeline of 10-day chronic social defeat stress
289 (CSDS), social interaction (SI) and tissue collection. **F**, Individual SI values after 10-day CSDS exposure. **G**,
290 Quantitative PCR revealed significant decrease of mRNA levels for *Aqp4* gene in stress susceptible (SS) male mice
291 when compared to unstressed control (CTRL) and resilient (RES) animals (left) which correlates with *Cldn5* stress-
292 induced expression changes (right). **H**, Schematic of astrocytic end-feet and endothelial cells. **I**, Individual SI values
293 for male CSDS. **J**, Astrocytic end-feet coverage of NAc shell vessels is lower following CSDS for SS mice without
294 reaching significance. **K**, CSDS induces decreased vessel volume in SS mice not observed in RES and CTRL. **L**, RES
295 mice are characterized by increased number of endothelial cells colocalizing with CB1 in the NAc shell as compared
296 to SS and CTRL animals (left), and it correlates with social interactions (right). **M**, Representative images of CB1,
297 *Aqp4* and CD31 immunohistochemistry in the NAc shell after social defeat stress, scale bars, 20 μ m, **N**, Stimulated
298 emission depletion (STED) representative image of CB1, *Aqp4* and Cd31 immunohistochemistry in the NAc shell of
299 CTRL mice. Representative images intensity was adjusted with log scale, Scale bars, 2 μ m. Data represent
300 mean \pm s.e.m.; number of animals or subjects (n) is indicated on graphs. For 2 groups analysis two-tailed t-test was
301 applied. In the case of 3 groups one-way ANOVA followed by Holm-Šidák's multiple comparison test was applied.
302 For n lower than 8, a Kruskal-Wallis test followed by Dunn's multiple comparisons evaluation was used; ****p \leq
303 0.0001, ***p \leq 0.001, **p \leq 0.01, *p \leq 0.05.

304


305 **The NAc astrocytic endocannabinoidome is modulated by stress exposure and associated** 306 **inflammation.**

307 Stress-induced alterations in CB1-related signaling modulates neuronal synaptic plasticity
308 in the NAc leading to behavioral adaptations^{12,39}. Contribution of astrocytic CB1-related signaling
309 in this brain region and behaviors is undetermined, thus, we next aim to gain mechanistic insights.
310 Acting on CB1 with different affinity are two main ECs: 2-arachidonoylglycerol (2-AG) and N-
311 arachidonylethanolamine or anandamide (AEA)⁴⁰ (**Fig.5A**). Basal brain levels of 2-AG are ~200-
312 fold higher than those of AEA⁴¹. Mice were subjected to 10-day CSDS then the NAc was dissected
313 from CTRL, SS and RES animals and 2-AG and AEA levels assessed using high-pressure liquid
314 chromatography with mass spectrometry (HPLC-MS/MS) (**Fig.5B**). While no difference was
315 noted for AEA (**Supp.Fig.5B**), 2-AG changes were linked with resilience (*p=0.0307) and
316 correlated with social interactions following stress exposure (*p=0.0336) (**Fig.5C-D**). Astrocytes
317 altogether with neurons regulate 2-AG content and endocannabinoid-dependent signalling⁴² but
318 astrocyte specific implication in the NAc stress responses remains unknown. AEA biosynthesis
319 primarily rely on N-acylphosphatidylethanolamine (Nape)-specific phospholipase D-like
320 hydrolase (*Nape-Pld*) whereas fatty acid amide hydrolase (*Faah*) is the main enzyme responsible
321 for AEA hydrolysis^{43,44}. As for 2-AG, diacylglycerol lipase α (*Dagla*) is the primary enzyme
322 synthesizing it in both neurons and astrocytes⁴⁵. Finally, 2-AG is primarily hydrolysed by
323 monoacylglycerol lipase (*Magl*)⁴³ (**Fig.5A**). 10-day CSDS increased NAc expression of *Dagla*
324 (**p=0.0018) and *Nape-Pld* (**p=0.0095) (**Supp.Fig.5C**) suggesting compensatory mechanisms
325 in this brain area. We next assessed if stress alters endocannabinoid enzyme function in NAc
326 astrocytes by taking advantage of fluorescence-activated cell sorting (FACS) for region- and cell-
327 specific isolation following CSDS (**Fig.5E-F**, **Supp.Fig.5D**). CSDS seems to elevate astrocytic
328 *Mgl* and *Dagla* expression in stressed mice while decreasing *Nape-Pld* (**Fig.5G**, **Supp.Fig.5F-**
329 **G**). Due to technical limitations to characterize endocannabinoid signaling in a cell- and region-

330 specific manner with sufficient power samples for individual animals, we chose to complement
331 our *in vivo* studies with *in vitro* experiments.

332 Reduced BBB integrity in the NAc of SS mice is associated with depression-like behaviors
333 but also passage of peripheral interleukin-6 (IL-6)⁵. This proinflammatory cytokine has been
334 linked to stress-related disorders and is elevated in the blood of individuals with MDD particularly
335 those resistant to treatment^{46,47}. Perivascular astrocytic CB1 receptors are well positioned to sense
336 and react to stress-associated circulating inflammation possibly contributing to neurovascular
337 adaptations leading to vulnerability vs resilience. To evaluate if CB1-dependent endocannabinoid
338 signaling is altered by IL-6 in this cell population, mouse astrocytes were isolated and cultured *in*
339 *vitro*⁴⁸ (**Fig.5H, Supp.Fig.5H-I**). Acute treatment with IL-6 (100ng/ul) led to an increase in
340 astrocytic *IL-6* expression (3h: **p=0.0092; 6h: ****p<0.0001) in parallel with *Cnr1* (3h:
341 *p=0.0173; 6h: ***p=0.0008). Conversely, *Nape-Pld* decreased at the same points (3h:
342 **p=0.0039; 6h: *p=0.0361) with higher *Mgll* expression observed only after 6h (*p=0.0123)
343 (**Fig.5H**). This is well in line with the changes observed following CSDS and reported above
344 (**Fig.5G, Supp.Fig.5**). Importantly, alterations were not present anymore after 24h highlighting
345 the dynamic relationship between the ECS and IL-6. Considering the chronic nature of our stress
346 paradigm, cultured astrocytes were next treated for a longer period. Exposure to IL-6 (100ng/ul)
347 for 7 days promoted morphological changes with a loss in GFAP volume (**p=0.0005) (**Fig.5I-**
348 **J**). In fact, treatment with IL-6 for 24h was already sufficient to reduce astrocyte primary processes
349 (**p=0.0083), which could be linked to the loss of astrocyte endfeet coverage reported in MDD¹⁶.
350 Since overexpression of astrocytic *Cnr1* prevented stress-induced anxiety- and depression-like
351 behaviors (**Fig.3**), we tested if it could dampen IL-6-associated changes in astrocytes. Astrocytes
352 were transfected with either the AAV-GFAP-sham or AAV-GFAP-*Cnr1* virus prior treatment
353 with IL-6 (**Fig.5K**). High astrocytic *Cnr1* expression reduced IL-6-driven increase in *IL-6* (virus
354 x treatment effect *p=0.0480) along with the expected elevation of IL-6-driven *Cnr1* production
355 (virus effect: ****p<0.0001; virus x treatment effect ****p<0.0001) (**Fig.5K, Supp.Fig.5K-L**).
356 It also prevented *Aqp4* internalization caused by IL-6 treatment (**Fig.5L**) providing a mechanistic
357 link between *Cnr1* in astrocytes, stress-induced inflammation, BBB alterations and behavioral
358 responses.

359



361 **Figure 5. The astrocytic endocannabinoidome is modulated by stress exposure and associated inflammation.**
362 **A**, Schematic of endocannabinoid main enzymes responsible for their synthesis and degradation. Anandamide (AEA)
363 is mainly synthesized by N-acylphosphatidylethanolamide-phospholipase D (Nape-Pld) and metabolized by fatty acid
364 amidohydrolase (Faah). 2-arachidonoylglycerol (2-AG) is generated through the action of selective enzymes,
365 including diacylglycerol lipase (Dagl α) and is metabolized by both Faah and monoacylglycerol lipase (Magl). **B**,
366 Experimental timeline of 10-day chronic social defeat stress (CSDS), social interaction (SI) test and tissue collection.
367 **C**, Individual SI values following CSDS. **D**, CSDS decreases nucleus accumbens (NAc) 2-AG levels in resilient
368 (RES) but not in stress-susceptible (SS) males (left). It correlates with social interaction levels (right). **E**, To assess
369 NAc astrocyte-specific endocannabinoid changes induced by chronic stress, astrocytes were isolated using fluorescent
370 activated cell sorting (FACS). **F**, Transcriptomic analysis confirmed enrichment of astrocytes after FACS. **G**, A trend
371 for an increase in *Mgll* transcription was noted in stressed mice. **H**, *in vitro* experimental scheme for mouse primary
372 cultured astrocytes treated with pro-inflammatory interleukin-6 (IL-6, 100 ng/ul). Acute treatment with IL-6 drives
373 pro-inflammatory response in astrocytes leading to an increase of the endocannabinoidome gene transcription at 3h
374 and 6h time points. **I**, Chronic (7-d) but not acute (24h) treatment with IL-6 results in decreased volume of GFAP +
375 astrocytes (left). Both acute and chronic treatment led to decreased astrocyte morphology complexity (right). **J**,
376 Representative images of astrocytes expressing GFAP untreated (left), acutely (middle) or chronically (right) treated
377 with IL-6 (100 ng/ul). Scale bars, 20 μ m. **K**, Infection of cultured astrocytes with AAV-GFAP-*Cnr1* but not AAV-
378 GFAP-sham decreases pro-inflammatory response at the 6-h time point. IL-6 treatment increases expression of *Cnr1*
379 gene in AAV-infected astrocytes. **L**, Acute IL-6 treatment leads to Aquaporin-4 (Aqp4) depolarization from the
380 astrocyte end-feet to the nuclei, which is prevented by AAV-GFAP-*Cnr1* infection. Scale bars, 20 μ m. Data represent
381 mean \pm s.e.m.; number of animals or subjects (n) is indicated on graphs. For one factor analysis one-way ANOVA
382 followed by Holm-Šidák's multiple comparison test was applied. For n lower than 8, the Kruskal-Wallis test followed
383 by Dunn's multiple comparisons evaluation was used. For 2 groups analysis two-tailed t-test was applied. For analysis
384 with two factors, two-way ANOVA followed by Holm-Šidák's multiple comparison test was utilized; correlations
385 were evaluated with Pearson's correlation coefficient; ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05.


386

387

388 **Stress-induced changes in *Cnr1* are sex-specific and observed in the female prefrontal cortex.**

389 Stress-related disorders such as MDD are characterized by sex differences in prevalence,
390 symptomatology, and treatment response⁷. Sex-specific MDD transcriptional signatures have been
391 described in humans^{49,50} and differences in the NAc transcriptome profiles of male vs female mice
392 are associated with susceptibility vs resilience to stressors⁵¹. We recently reported that exposure
393 to stress alters the BBB in the PFC, and not the NAc, of female mice⁷. Accordingly, CLDN5 loss
394 noted in postmortem NAc samples from men with MDD⁶ was instead observed in the PFC of
395 women⁷, supporting a sex-specific impact of stress and mood disorders on the neurovasculature.
396 To evaluate if *Cnr1* could also be involved in female stress responses, female mice were subjected
397 to a modified 10-day CSDS⁷ as described by Harris et al⁵². Briefly, female C57Bl-6 mice were
398 exposed daily (10 min/day) to bouts of social defeats by a larger, physically aggressive CD-1 male
399 mouse after application of male CD-1 urine on the vagina, tail base, and upper back of the female
400 (**Fig.6A**). Consistent with stress-induced changes in BBB integrity, an increase in *Cnr1* was
401 measured in the PFC of RES females (*p=0.0153) with no change for the NAc (**Fig.6B-C**,
402 **Supp.Fig.6**). Like in the NAc of SS males (**Fig.4G**), *Aqp4* expression was lower in the PFC of SS
403 females (**p=0.0014) (**Fig.6D**). A baseline sex differences was noted in the unstressed control
404 groups with lower *Aqp4* (*p=0.0319) in the female NAc when compared to males and a trend for
405 *Cnr1* (p=0.0755) (**Fig.6E**). Regional brain difference was observed for *Cnr1* expression at baseline
406 with higher expression in the PFC when compared to NAc for males (**p=0.0028), a difference

407 even greater for females (***p*=0.0006) (**Fig.6F**). We next run a control experiment based on the
 408 previous observation that female rodents are generally considered more vulnerable to
 409 unpredictable stress⁵¹. Thus, other cohorts of mice were subjected to 28 days of chronic variable
 410 stress (CVS). This protocol consists in series of three different stressors namely foot shocks, tail
 411 suspension, or restraint stress (1/day) leading to the development of anxiety- and depression-like
 412 behavioral abnormalities to an equivalent degree in male and female mice⁴⁹. Brain samples were
 413 collected 24h after the last stressor then *Aqp4* and *Cnr1* were compared vs unstressed controls
 414 (**Fig.6G**). CVS induces a similar loss of *Aqp4* in the male NAc (***p*=0.0014) and female PFC
 415 (***p*=0.0035) (**Fig.6H-I**). As expected, no significant difference was measured for *Cnr1* in the
 416 absence of resilient animals following exposure to this stress paradigm. Altogether, these data
 417 suggest that chronic stress induces sex-specific regional changes in *Cnr1* expression in line with
 418 BBB alterations and strengthen our hypothesis that upregulation of *Cnr1* is strictly associated with
 419 resilience to stress.



420
 421 **Figure 6. Stress-induced changes in *Cnr1* are sex-specific and observed in the female PFC.** **A**, Experimental
 422 timeline of modified female 10-day chronic social defeat stress (CSDS), social interaction (SI) and tissue collection.
 423 **B**, Individual SI values (left) and representative heatmaps (right) of SI test after CSDS. **C**, Quantitative PCR revealed
 424 upregulation of *Cannabinoid receptor 1* (*Cnr1*) gene expression in the prefrontal cortex (PFC, right) but not the
 425 nucleus accumbens (NAc, left) of resilient (RES) female mice when compared to unstressed control (CTRL). **D**,
 426 *Aquaporin-4* (*Aqp4*) gene expression is decreased in the PFC (right) but not NAc (left) of stress-susceptible (SS)

427 females when compared to RES and CTRL animals. **E**, Transcriptomic analysis highlighted sex differences in baseline
428 gene expression of *Aqp4* (left) and *Cnr1* (right) in the NAc. **F**, *Cnr1* baseline mRNA levels exhibit regional differences
429 both in male (left) and female (right) mice. **G**, Experimental timeline of 28-d chronic variable stress (CVS), and tissue
430 collection. CVS induces transcriptional decrease for *Aqp4* (right) but not *Cnr1* (left) in (**H**) NAc of males and (**I**) PFC
431 of females. Data represent mean \pm s.e.m.; number of animals or subjects (n) is indicated on graphs. For one factor
432 analysis one-way ANOVA followed by Holm-Šidák's multiple comparison test was applied. For n lower than 8, the
433 Kruskal-Wallis test followed by Dunn's multiple comparisons evaluation was used. For 2 groups analysis two-tailed
434 t-test was used: ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05.

435


436

437 **Elevated astrocytic *Cnr1* expression in the NAc is associated with beneficial effects of** 438 **physical exercise and antidepressant treatments.**

439 Prevention and treatment of stress-related disorders remain challenging in psychiatry.
440 Physical exercise has been associated with stress resilience⁵³ and neurovascular health⁵⁴, however,
441 the biology underlying beneficial effects in the brain reward system is not completely understood.
442 The ECS is activated by physical exercise as measured by high levels of endocannabinoids in the
443 plasma⁵⁵, also in relation to stress and depression⁵⁶, leading us to hypothesize that it may influence
444 the BBB via perivascular astrocytic CB1. Male mice were subjected to the classical 10-day CSDS
445 paradigm but with access to a running wheel on their side of the cage (**Fig.7A**). The impact of
446 chronic social stress exposure was still present with about 50% RES vs 50% SS animals (**Fig.7B**).
447 However, decreased time spent in the interaction zone during the SI test remained significant only
448 for mice without access to voluntary exercise (stress effect: ***p=0.0009; PE effect **p=0.0037)
449 (**Fig.7C, Supp.Fig.7A**). Total running distance was similar between groups (**Supp.Fig.7B**) though
450 RES mice spent more time running during daytime (***p=0.0009) mainly in the hour immediately
451 following social defeat, which could represent a stress coping strategy (**Fig.7D, Supp.Fig.7C**). In
452 fact, high daytime running was correlated with elevated *Cnr1* expression in the NAc (**p=0.0026)
453 (**Fig.7E**). To confirm cell specificity of physical exercise effect on *Cnr1*, RNA scope was
454 combined with immunofluorescence to identify endothelial cell (CD31) and astrocyte endfeet
455 (*Aqp4*). Colocalization of *Cnr1* positive dots on the neurovasculature was more often observed in
456 RES animals (**Fig.7F**). Our results indicate that physical exercise could modulate BBB properties
457 via astrocytic perivascular *Cnr1* upregulation, thus promoting stress resilience.

458 Antidepressants are recommended for moderate to severe depression. However, 30-50%
459 of individuals with MDD are not responsive to classical drugs targeting neurons reflecting that
460 causal mechanisms, such as elevated circulating inflammation⁴⁶ or vascular dysfunction⁹, remain
461 untreated. To better understand the biology behind treatment response vs resistance and possible
462 involvement of astrocytic CB1, male mice were subjected to 10-day CSDS then unstressed CTRL
463 and SS animals treated i.p. for 2-3 weeks with either imipramine or fluoxetine, a tricyclic
464 antidepressant and selective serotonin reuptake inhibitor, respectively (**Fig.7G**). Imipramine
465 reverses transcriptional changes associated with stress susceptibility induced by CSDS, including
466 in the NAc⁵⁷, while fluoxetine acts on astrocyte morphology and plasticity⁵⁸. The 2nd SI test
467 performed after treatment revealed a positive impact of treatment on social interactions (stress x
468 treatment effect: *p=0.048) (**Fig.7H, Supp.Fig.7D**). Further analysis highlighted two groups of
469 SS-treated mice – responder and non-responders – when SI test performance was compared for
470 each individual. *Cnr1* expression was increased in the NAc of responders only (***p=0.001) and
471 this elevation correlated with higher level of *Aqp4* in this brain area (**p=0.0011) (**Fig.7I**).
472 Finally, the translational value of our mouse findings was assessed by measuring astrocytic *Cnr1*
473 expression in postmortem NAc tissue from individuals with MDD using RNA scope, confirming

474 a loss of *Cnr1*+ astrocytes (Aqp4+) in the MDD brain (**p*=0.0107). Conversely, antidepressant
 475 treatment was associated with a level of astrocytic *Cnr1* similar to controls (**Fig.7J-K**).
 476



477
 478 **Figure 7. Physical exercise and antidepressant treatment promote stress resilience and increase *Cnr1* in the**

479 **nucleus accumbens.** **A**, Experimental timeline of 10-day chronic social defeat stress (CSDS) with physical exercise,
480 social interaction (SI) and tissue collection. **B**, Individual SI values (left) and representative heatmaps (right) after
481 CSDS. **C**, Physical exercise prevents development of social deficits following CSDS. **D**, Resilient (RES) animals are
482 characterized by increased daytime running suggesting a coping strategy when facing CSDS exposure. **E**, Increased
483 transcription of *Cannabinoid receptor 1* (*Cnr1*) is observed in RES animals (left) and correlates with the level of
484 physical exercise during daytime (right). **F**, Representative RNA scope and immunofluorescence images exhibiting
485 increased *Cnr1* expression at the BBB (CD31 as endothelial cell marker) in the RES phenotype. Scale bar 10 μ m. **G**,
486 Experimental timeline of CSDS followed by an SI test to establish phenotype prior antidepressant treatment. A 2nd SI
487 test was performed 24h before tissue collection. **H**, Individual SI values (left) and representative heatmaps (right) for
488 these cohorts. **I**, Comparison of SI values (left) for treatment responders' vs non-responders. *Cnr1* mRNA level is
489 increased in the nucleus accumbens (NAc) of treatment responders only (middle) and it correlates with *Aquaporin-4*
490 (*Aqp4*) mRNA expression in this brain area (right). **J**, A loss in *Aqp4* positive cells expressing *Cnr1* is noted in men
491 with MDD. This alteration was not observed for individuals undergoing treatment (right). **K**, Representative RNA
492 scope images, scale bar 20 μ m. Data represent mean \pm s.e.m.; number of animals or subjects (n) is indicated on graphs.
493 One-way ANOVA or Brown-Forsythe ANOVA test followed by Holm-Šidák's or Dunnett's multiple comparison test
494 was applied. Two-way ANOVA or non-parametric Two-way ANOVA on Ranks followed by Holm-Šidák's or Wilcox
495 multiple comparison test was applied; For N lower than 8, Kruskal-Wallis test followed by Dunn's multiple
496 comparisons evaluation was used; correlations were evaluated with Pearson's correlation coefficient; ****p<0.0001,
497 ***p<0.001, **p<0.01, *p<0.05.

498
499

500 **Discussion**

501 CB1 signaling can promote positive adaptation following social stress exposure^{12,27}.
502 Indeed, striatal CB1 activation in neurons protects against CSDS-induced anxiety¹², while
503 treatment with a CB1 agonist attenuates stress-induced neuroinflammation and anxiety-like
504 behavior⁵⁹. Thus, it has been suggested that CB1 receptors can facilitate the activation of resilience
505 factors during and/or after stress exposure^{11,60,61}. Nonetheless, the exact mechanisms remain
506 elusive. An elegant study recently implicated astroglial mitochondria and glucose metabolism in
507 endocannabinoid-related regulation of social behaviors¹⁸. However, perivascular astrocytic CB1
508 receptors are understudied¹⁹ and their potential role in regulating chronic stress response had yet
509 to be investigated. Here we show that stress resilience is linked to an increase in astrocytic *Cnr1*
510 expression in the NAc shell, a subregion controlling reward-seeking behavior⁶². We localized
511 these changes at the BBB interface by taking advantage of super resolution microscopy.
512 Astrocytes are essential for BBB recovery after brain injury^{63,64}. They are actively involved in
513 maintaining BBB integrity by regulating tight junction formation^{65,66} and thus may directly
514 contribute to prevent stress-induced loss of Cldn5.

515 Additionally, we report that upregulation of astrocytic *Cnr1* in the NAc shell dampens
516 inflammation and stress-associated neurovascular alterations promoting resilience. To bypass the
517 limitations of CB1 antibodies specificity⁶⁷, we developed an astrocyte specific AAV driving *Cnr1*
518 expression within this cell type, whereas previous cell-specific *Cnr1* manipulations had mainly
519 focused on neuronal populations⁶⁸. To our knowledge this is the first viral strategy applied to
520 increase *Cnr1* expression in astrocytes in a region-selective manner. CB1 receptors are important
521 regulators of anxiety⁶⁹ with *Cnr1*^{-/-} knockout animals exhibiting anxiolytic drug resistance and
522 increased anxiety-like behavior under highly aversive conditions⁶⁹. Following viral-mediated
523 *Cnr1* overexpression in GFAP+ astrocytes of the NAc shell we observed baseline anxiolytic
524 effects. Mutant mice lacking *Cnr1* are characterized by reduced social interactions⁷⁰ which has
525 been linked with NAc shell function⁷¹. We expand these findings by highlighting a protective role
526 for astrocytic CB1 in the context of chronic social stress exposure with reduced social avoidance,
527 anxiety, and helplessness.

528 Not only CB1 itself but also its related signaling lipids are essential for positive stress
529 adaptation¹¹. 2-AG signaling within the NAc regulates anxiety and stress vulnerability as shown
530 previously using pharmacological approaches^{12,39}. Here, CSDS decreased 2-AG levels in NAc
531 punches that negatively correlated with social behaviors. This finding encourages cell specific
532 analysis as astrocytic 2-AG hydrolysis is mainly responsible for conversion to neuroinflammatory
533 mediators⁴². When we analyzed astrocyte-specific expression of EC metabolic enzymes, we found
534 that those regulating 2-AG levels tended to be increased in the NAc astrocytes of RES mice.
535 Additionally, stress-induced alterations in EC levels are transient due to rapid hydrolysis⁷². In the
536 future, therefore, it will be important to evaluate EC signaling dynamics at different time points in
537 mice, ideally in a cell-specific manner, following stress exposure. Additionally, our *in vitro*
538 findings indicated that both astrocytic *Cnr1* and *Mgll* are altered by an immune challenge after
539 only a few hours. Change in 2-AG level via lower expression of its main degrading enzyme Magl
540 has implication for astrocyte response to neuroinflammation^{73,74}. In fact, viral-mediated increase
541 of *Cnr1* in astrocytes reduced IL-6 driven deleterious inflammatory changes and morphological
542 impairments including loss of endfeet-related Aqp4 which has been associated to depression
543 pathogenesis^{16,38}. Circulating inflammation is elevated in stressed animals and subpopulations of
544 individuals with MDD particularly those resisting to treatments^{46,47,75}. Astrocyte endfeet are
545 perfectly positioned to sense circulating inflammation and react to it, particularly in the context of
546 BBB breakdown and loss of tight junctions⁹ as observed following CSDS and in the MDD brain.

547 Altogether, our findings support an active role of the BBB, via astrocyte endfeet, in stress
548 resilience. Importantly, our results complement evidence suggesting that chronic stress affect the
549 neurovasculature in a sex-specific manner⁵⁻⁷ which may contribute to sex differences reported in
550 MDD prevalence, symptomatology, and treatment response⁷⁶. *Cnr1* upregulation was observed in
551 the PFC but not NAc of female mice, highlighting the importance of studying sex differences in
552 the context of stress-related disorders including for the neurovascular unit and ECS.
553 Polymorphisms of the EC receptor genes (*CNR1* and *CNR2*) have been associated with MDD⁷⁷
554 and could influence vulnerability to psychosocial adversity⁷⁸. Anti-obesity treatment with CB1
555 antagonist rimonabant increases the risk of anxiety and mood disorders⁷⁹. In rodent models of
556 depression, treatment with antidepressants imipramine or fluoxetine, alters striatal CB1 receptor
557 density⁸⁰ and expression in neuronal cells⁸¹. In parallel, voluntary exercise enhances CB1
558 sensitivity in the striatum⁸². Here, we observed that both interventions increased expression of
559 perivascular *Cnr1*.

560 To summarize, we propose that perivascular *Cnr1* plays an important role in modulating
561 stress responses in mice and possibly MDD. Identification of beneficial EC-related adaptations
562 within the BBB can represent a promising approach to develop innovative therapies for mood
563 disorders.

564

565

566 **References**

567 1 Menard, C., Pfau, M. L., Hodes, G. E. & Russo, S. J. Immune and Neuroendocrine
568 Mechanisms of Stress Vulnerability and Resilience. *Neuropsychopharmacology* **42**, 62-
569 80 (2017). <https://doi.org/10.1038/npp.2016.90>

570 2 Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R. & Walters, E. E. Prevalence,
571 severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity
572 Survey Replication. *Arch Gen Psychiatry* **62**, 617-627 (2005).
573 <https://doi.org/10.1001/archpsyc.62.6.617>

574 3 Diseases, G. B. D. & Injuries, C. Global burden of 369 diseases and injuries in 204
575 countries and territories, 1990-2019: a systematic analysis for the Global Burden of
576 Disease Study 2019. *Lancet* **396**, 1204-1222 (2020). [https://doi.org/10.1016/S0140-6736\(20\)30925-9](https://doi.org/10.1016/S0140-6736(20)30925-9)

578 4 Meltzer, H., Vostanis, P., Ford, T., Bebbington, P. & Dennis, M. S. Victims of bullying
579 in childhood and suicide attempts in adulthood. *Eur Psychiatry* **26**, 498-503 (2011).
580 <https://doi.org/10.1016/j.eurpsy.2010.11.006>

581 5 Menard, C. *et al.* Social stress induces neurovascular pathology promoting depression.
582 *Nat Neurosci* **20**, 1752-1760 (2017). <https://doi.org/10.1038/s41593-017-0010-3>

583 6 Dudek, K. A. *et al.* Molecular adaptations of the blood-brain barrier promote stress
584 resilience vs. depression. *Proc Natl Acad Sci U S A* **117**, 3326-3336 (2020).
585 <https://doi.org/10.1073/pnas.1914655117>

586 7 Dion-Albert, L. *et al.* Vascular and blood-brain barrier-related changes underlie stress
587 responses and resilience in female mice and depression in human tissue. *Nat Commun*
588 **13**, 164 (2022). <https://doi.org/10.1038/s41467-021-27604-x>

589 8 Keaney, J. & Campbell, M. The dynamic blood-brain barrier. *FEBS J* **282**, 4067-4079
590 (2015). <https://doi.org/10.1111/febs.13412>

591 9 Dion-Albert, L., Dudek, K. A., Russo, S. J., Campbell, M. & Menard, C. Neurovascular
592 adaptations modulating cognition, mood, and stress responses. *Trends Neurosci* **46**, 276-
593 292 (2023). <https://doi.org/10.1016/j.tins.2023.01.005>

594 10 Cheng, Y. *et al.* TNFalpha disrupts blood brain barrier integrity to maintain prolonged
595 depressive-like behavior in mice. *Brain Behav Immun* **69**, 556-567 (2018).
596 <https://doi.org/10.1016/j.bbi.2018.02.003>

597 11 Hill, M. N. *et al.* Endogenous cannabinoid signaling is essential for stress adaptation.
598 *Proc Natl Acad Sci U S A* **107**, 9406-9411 (2010).
599 <https://doi.org/10.1073/pnas.0914661107>

600 12 Bosch-Bouju, C., Larrieu, T., Linders, L., Manzoni, O. J. & Laye, S. Endocannabinoid-
601 Mediated Plasticity in Nucleus Accumbens Controls Vulnerability to Anxiety after Social
602 Defeat Stress. *Cell Rep* **16**, 1237-1242 (2016).
603 <https://doi.org/10.1016/j.celrep.2016.06.082>

604 13 Hill, M. N., Miller, G. E., Ho, W. S., Gorzalka, B. B. & Hillard, C. J. Serum
605 endocannabinoid content is altered in females with depressive disorders: a preliminary
606 report. *Pharmacopsychiatry* **41**, 48-53 (2008). <https://doi.org/10.1055/s-2007-993211>

607 14 Di Marzo, V., Bifulco, M. & De Petrocellis, L. The endocannabinoid system and its
608 therapeutic exploitation. *Nat Rev Drug Discov* **3**, 771-784 (2004).
609 <https://doi.org/10.1038/nrd1495>

610 15 Abbott, N. J., Ronnback, L. & Hansson, E. Astrocyte-endothelial interactions at the
611 blood-brain barrier. *Nat Rev Neurosci* **7**, 41-53 (2006). <https://doi.org/10.1038/nrn1824>

- 612 16 Rajkowska, G., Hughes, J., Stockmeier, C. A., Javier Miguel-Hidalgo, J. & Maciag, D.
613 Coverage of blood vessels by astrocytic endfeet is reduced in major depressive disorder.
614 *Biol Psychiatry* **73**, 613-621 (2013). <https://doi.org:10.1016/j.biopsych.2012.09.024>
- 615 17 Eraso-Pichot, A. *et al.* Endocannabinoid signaling in astrocytes. *Glia* **71**, 44-59 (2023).
616 <https://doi.org:10.1002/glia.24246>
- 617 18 Jimenez-Blasco, D. *et al.* Glucose metabolism links astroglial mitochondria to
618 cannabinoid effects. *Nature* **583**, 603-608 (2020). [https://doi.org:10.1038/s41586-020-](https://doi.org:10.1038/s41586-020-2470-y)
619 [2470-y](https://doi.org:10.1038/s41586-020-2470-y)
- 620 19 Marsicano, G. & Araque, A. Of glue and pot: Endocannabinoid signaling in glial cells.
621 *Glia* **71**, 3-4 (2023). <https://doi.org:10.1002/glia.24296>
- 622 20 Golden, S. A., Covington, H. E., 3rd, Berton, O. & Russo, S. J. A standardized protocol
623 for repeated social defeat stress in mice. *Nat Protoc* **6**, 1183-1191 (2011).
624 <https://doi.org:10.1038/nprot.2011.361>
- 625 21 Russo, S. J. & Nestler, E. J. The brain reward circuitry in mood disorders. *Nat Rev*
626 *Neurosci* **14**, 609-625 (2013). <https://doi.org:10.1038/nrn3381>
- 627 22 Zhang, Z. *et al.* The Appropriate Marker for Astrocytes: Comparing the Distribution and
628 Expression of Three Astrocytic Markers in Different Mouse Cerebral Regions. *Biomed*
629 *Res Int* **2019**, 9605265 (2019). <https://doi.org:10.1155/2019/9605265>
- 630 23 Zahm, D. S. Functional-anatomical implications of the nucleus accumbens core and shell
631 subterritories. *Ann N Y Acad Sci* **877**, 113-128 (1999). [https://doi.org:10.1111/j.1749-](https://doi.org:10.1111/j.1749-6632.1999.tb09264.x)
632 [6632.1999.tb09264.x](https://doi.org:10.1111/j.1749-6632.1999.tb09264.x)
- 633 24 Voorn, P., Vanderschuren, L. J., Groenewegen, H. J., Robbins, T. W. & Pennartz, C. M.
634 Putting a spin on the dorsal-ventral divide of the striatum. *Trends Neurosci* **27**, 468-474
635 (2004). <https://doi.org:10.1016/j.tins.2004.06.006>
- 636 25 Carelli, R. M. Nucleus accumbens cell firing and rapid dopamine signaling during goal-
637 directed behaviors in rats. *Neuropharmacology* **47 Suppl 1**, 180-189 (2004).
638 <https://doi.org:10.1016/j.neuropharm.2004.07.017>
- 639 26 Saddoris, M. P., Cacciapaglia, F., Wightman, R. M. & Carelli, R. M. Differential
640 Dopamine Release Dynamics in the Nucleus Accumbens Core and Shell Reveal
641 Complementary Signals for Error Prediction and Incentive Motivation. *J Neurosci* **35**,
642 11572-11582 (2015). <https://doi.org:10.1523/JNEUROSCI.2344-15.2015>
- 643 27 Beins, E. C. *et al.* Cannabinoid receptor 1 signalling modulates stress susceptibility and
644 microglial responses to chronic social defeat stress. *Transl Psychiatry* **11**, 164 (2021).
645 <https://doi.org:10.1038/s41398-021-01283-0>
- 646 28 Dubreucq, S. *et al.* Genetic dissection of the role of cannabinoid type-1 receptors in the
647 emotional consequences of repeated social stress in mice. *Neuropsychopharmacology* **37**,
648 1885-1900 (2012). <https://doi.org:10.1038/npp.2012.36>
- 649 29 Ducottet, C., Aubert, A. & Belzung, C. Susceptibility to subchronic unpredictable stress
650 is related to individual reactivity to threat stimuli in mice. *Behav Brain Res* **155**, 291-299
651 (2004). <https://doi.org:10.1016/j.bbr.2004.04.020>
- 652 30 Hind, W. H. *et al.* Endocannabinoids modulate human blood-brain barrier permeability
653 in vitro. *Br J Pharmacol* **172**, 3015-3027 (2015). <https://doi.org:10.1111/bph.13106>
- 654 31 Panikashvili, D. *et al.* The endocannabinoid 2-AG protects the blood-brain barrier after
655 closed head injury and inhibits mRNA expression of proinflammatory cytokines.
656 *Neurobiol Dis* **22**, 257-264 (2006). <https://doi.org:10.1016/j.nbd.2005.11.004>
- 657 32 Wang, Z., Li, Y., Cai, S., Li, R. & Cao, G. Cannabinoid receptor 2 agonist attenuates

658 blood-brain barrier damage in a rat model of intracerebral hemorrhage by activating the
659 Rac1 pathway. *Int J Mol Med* **42**, 2914-2922 (2018).
660 <https://doi.org/10.3892/ijmm.2018.3834>
661 33 Nitta, T. *et al.* Size-selective loosening of the blood-brain barrier in claudin-5-deficient
662 mice. *J Cell Biol* **161**, 653-660 (2003). <https://doi.org/10.1083/jcb.200302070>
663 34 Vanlandewijck, M. *et al.* A molecular atlas of cell types and zonation in the brain
664 vasculature. *Nature* **554**, 475-480 (2018). <https://doi.org/10.1038/nature25739>
665 35 Campbell, M. *et al.* Systemic low-molecular weight drug delivery to pre-selected
666 neuronal regions. *EMBO Mol Med* **3**, 235-245 (2011).
667 <https://doi.org/10.1002/emmm.201100126>
668 36 Yosef, N., Xi, Y. & McCarty, J. H. Isolation and transcriptional characterization of
669 mouse perivascular astrocytes. *PLoS One* **15**, e0240035 (2020).
670 <https://doi.org/10.1371/journal.pone.0240035>
671 37 Wei, F. *et al.* Chronic stress impairs the aquaporin-4-mediated glymphatic transport
672 through glucocorticoid signaling. *Psychopharmacology (Berl)* **236**, 1367-1384 (2019).
673 <https://doi.org/10.1007/s00213-018-5147-6>
674 38 Genel, O., Pariante, C. M. & Borsini, A. The role of AQP4 in the pathogenesis of
675 depression, and possible related mechanisms. *Brain Behav Immun* **98**, 366-377 (2021).
676 <https://doi.org/10.1016/j.bbi.2021.08.232>
677 39 Wang, W. *et al.* Deficiency in endocannabinoid signaling in the nucleus accumbens
678 induced by chronic unpredictable stress. *Neuropsychopharmacology* **35**, 2249-2261
679 (2010). <https://doi.org/10.1038/npp.2010.99>
680 40 Di Marzo, V. New approaches and challenges to targeting the endocannabinoid system.
681 *Nat Rev Drug Discov* **17**, 623-639 (2018). <https://doi.org/10.1038/nrd.2018.115>
682 41 Sugiura, T., Kishimoto, S., Oka, S. & Gokoh, M. Biochemistry, pharmacology and
683 physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. *Prog*
684 *Lipid Res* **45**, 405-446 (2006). <https://doi.org/10.1016/j.plipres.2006.03.003>
685 42 Viader, A. *et al.* Metabolic Interplay between Astrocytes and Neurons Regulates
686 Endocannabinoid Action. *Cell Rep* **12**, 798-808 (2015).
687 <https://doi.org/10.1016/j.celrep.2015.06.075>
688 43 Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T. & Ueda, N. Molecular characterization
689 of a phospholipase D generating anandamide and its congeners. *J Biol Chem* **279**, 5298-
690 5305 (2004). <https://doi.org/10.1074/jbc.M306642200>
691 44 Cravatt, B. F. *et al.* Molecular characterization of an enzyme that degrades
692 neuromodulatory fatty-acid amides. *Nature* **384**, 83-87 (1996).
693 <https://doi.org/10.1038/384083a0>
694 45 Viader, A. *et al.* A chemical proteomic atlas of brain serine hydrolases identifies cell
695 type-specific pathways regulating neuroinflammation. *Elife* **5**, e12345 (2016).
696 <https://doi.org/10.7554/eLife.12345>
697 46 Hodes, G. E., Kana, V., Menard, C., Merad, M. & Russo, S. J. Neuroimmune
698 mechanisms of depression. *Nat Neurosci* **18**, 1386-1393 (2015).
699 <https://doi.org/10.1038/nn.4113>
700 47 Hodes, G. E., Menard, C. & Russo, S. J. Integrating Interleukin-6 into depression
701 diagnosis and treatment. *Neurobiol Stress* **4**, 15-22 (2016).
702 <https://doi.org/10.1016/j.ynstr.2016.03.003>
703 48 Schildge, S., Bohrer, C., Beck, K. & Schachtrup, C. Isolation and culture of mouse

704 cortical astrocytes. *J Vis Exp* (2013). <https://doi.org:10.3791/50079>

705 49 Labonte, B. *et al.* Sex-specific transcriptional signatures in human depression. *Nat Med*
706 **23**, 1102-1111 (2017). <https://doi.org:10.1038/nm.4386>

707 50 Seney, M. L. *et al.* Opposite Molecular Signatures of Depression in Men and Women.
708 *Biol Psychiatry* **84**, 18-27 (2018). <https://doi.org:10.1016/j.biopsych.2018.01.017>

709 51 Hodes, G. E. *et al.* Sex Differences in Nucleus Accumbens Transcriptome Profiles
710 Associated with Susceptibility versus Resilience to Subchronic Variable Stress. *J*
711 *Neurosci* **35**, 16362-16376 (2015). <https://doi.org:10.1523/JNEUROSCI.1392-15.2015>

712 52 Harris, A. Z. *et al.* A Novel Method for Chronic Social Defeat Stress in Female Mice.
713 *Neuropsychopharmacology* **43**, 1276-1283 (2018). <https://doi.org:10.1038/npp.2017.259>

714 53 Mul, J. D. *et al.* Voluntary wheel running promotes resilience to chronic social defeat
715 stress in mice: a role for nucleus accumbens DeltaFosB. *Neuropsychopharmacology* **43**,
716 1934-1942 (2018). <https://doi.org:10.1038/s41386-018-0103-z>

717 54 Bliss, E. S., Wong, R. H., Howe, P. R. & Mills, D. E. Benefits of exercise training on
718 cerebrovascular and cognitive function in ageing. *J Cereb Blood Flow Metab* **41**, 447-
719 470 (2021). <https://doi.org:10.1177/0271678X20957807>

720 55 Stone, N. L. *et al.* An Analysis of Endocannabinoid Concentrations and Mood Following
721 Singing and Exercise in Healthy Volunteers. *Front Behav Neurosci* **12**, 269 (2018).
722 <https://doi.org:10.3389/fnbeh.2018.00269>

723 56 Heyman, E. *et al.* Intense exercise increases circulating endocannabinoid and BDNF
724 levels in humans--possible implications for reward and depression.
725 *Psychoneuroendocrinology* **37**, 844-851 (2012).
726 <https://doi.org:10.1016/j.psyneuen.2011.09.017>

727 57 Bagot, R. C. *et al.* Ketamine and Imipramine Reverse Transcriptional Signatures of
728 Susceptibility and Induce Resilience-Specific Gene Expression Profiles. *Biol Psychiatry*
729 **81**, 285-295 (2017). <https://doi.org:10.1016/j.biopsych.2016.06.012>

730 58 Czeh, B., Simon, M., Schmelting, B., Hiemke, C. & Fuchs, E. Astroglial plasticity in the
731 hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine
732 treatment. *Neuropsychopharmacology* **31**, 1616-1626 (2006).
733 <https://doi.org:10.1038/sj.npp.1300982>

734 59 Lisboa, S. F. *et al.* Repeated social defeat-induced neuroinflammation, anxiety-like
735 behavior and resistance to fear extinction were attenuated by the cannabinoid receptor
736 agonist WIN55,212-2. *Neuropsychopharmacology* **43**, 1924-1933 (2018).
737 <https://doi.org:10.1038/s41386-018-0064-2>

738 60 Lutz, B., Marsicano, G., Maldonado, R. & Hillard, C. J. The endocannabinoid system in
739 guarding against fear, anxiety and stress. *Nat Rev Neurosci* **16**, 705-718 (2015).
740 <https://doi.org:10.1038/nrn4036>

741 61 Bedse, G., Hill, M. N. & Patel, S. 2-Arachidonoylglycerol Modulation of Anxiety and
742 Stress Adaptation: From Grass Roots to Novel Therapeutics. *Biol Psychiatry* **88**, 520-530
743 (2020). <https://doi.org:10.1016/j.biopsych.2020.01.015>

744 62 Lind, E. B. *et al.* A quadruple dissociation of reward-related behaviour in mice across
745 excitatory inputs to the nucleus accumbens shell. *Commun Biol* **6**, 119 (2023).
746 <https://doi.org:10.1038/s42003-023-04429-6>

747 63 Schreiner, B. *et al.* Astrocyte Depletion Impairs Redox Homeostasis and Triggers
748 Neuronal Loss in the Adult CNS. *Cell Rep* **12**, 1377-1384 (2015).
749 <https://doi.org:10.1016/j.celrep.2015.07.051>

750 64 Tsai, H. H. *et al.* Regional astrocyte allocation regulates CNS synaptogenesis and repair.
751 *Science* **337**, 358-362 (2012). <https://doi.org/10.1126/science.1222381>

752 65 Lee, S. W. *et al.* SSeCKS regulates angiogenesis and tight junction formation in blood-
753 brain barrier. *Nat Med* **9**, 900-906 (2003). <https://doi.org/10.1038/nm889>

754 66 Janzer, R. C. & Raff, M. C. Astrocytes induce blood-brain barrier properties in
755 endothelial cells. *Nature* **325**, 253-257 (1987). <https://doi.org/10.1038/325253a0>

756 67 Grimsey, N. L. *et al.* Specific detection of CB1 receptors; cannabinoid CB1 receptor
757 antibodies are not all created equal! *J Neurosci Methods* **171**, 78-86 (2008).
758 <https://doi.org/10.1016/j.jneumeth.2008.02.014>

759 68 Rey, A. A., Purrio, M., Viveros, M. P. & Lutz, B. Biphasic effects of cannabinoids in
760 anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and
761 glutamatergic neurotransmission. *Neuropsychopharmacology* **37**, 2624-2634 (2012).
762 <https://doi.org/10.1038/npp.2012.123>

763 69 Haller, J., Varga, B., Ledent, C., Barna, I. & Freund, T. F. Context-dependent effects of
764 CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. *Eur J*
765 *Neurosci* **19**, 1906-1912 (2004). <https://doi.org/10.1111/j.1460-9568.2004.03293.x>

766 70 Litvin, Y., Phan, A., Hill, M. N., Pfaff, D. W. & McEwen, B. S. CB1 receptor signaling
767 regulates social anxiety and memory. *Genes Brain Behav* **12**, 479-489 (2013).
768 <https://doi.org/10.1111/gbb.12045>

769 71 Park, G. *et al.* Social isolation impairs the prefrontal-nucleus accumbens circuit
770 subserving social recognition in mice. *Cell Rep* **35**, 109104 (2021).
771 <https://doi.org/10.1016/j.celrep.2021.109104>

772 72 Katona, I. & Freund, T. F. Multiple functions of endocannabinoid signaling in the brain.
773 *Annu Rev Neurosci* **35**, 529-558 (2012). <https://doi.org/10.1146/annurev-neuro-062111-150420>

774 73 Zhu, D., Zhang, J., Hashem, J., Gao, F. & Chen, C. Inhibition of 2-arachidonoylglycerol
775 degradation enhances glial immunity by single-cell transcriptomic analysis. *J*
776 *Neuroinflammation* **20**, 17 (2023). <https://doi.org/10.1186/s12974-023-02701-4>

777 74 Grabner, G. F. *et al.* Deletion of Monoglyceride Lipase in Astrocytes Attenuates
778 Lipopolysaccharide-induced Neuroinflammation. *J Biol Chem* **291**, 913-923 (2016).
779 <https://doi.org/10.1074/jbc.M115.683615>

780 75 Hodes, G. E. *et al.* Individual differences in the peripheral immune system promote
781 resilience versus susceptibility to social stress. *Proc Natl Acad Sci U S A* **111**, 16136-
782 16141 (2014). <https://doi.org/10.1073/pnas.1415191111>

783 76 Dion-Albert, L. *et al.* Sex differences in the blood-brain barrier: Implications for mental
784 health. *Front Neuroendocrinol* **65**, 100989 (2022).
785 <https://doi.org/10.1016/j.yfrne.2022.100989>

786 77 Kong, X. *et al.* The association of endocannabinoid receptor genes (CNR1 and CNR2)
787 polymorphisms with depression: A meta-analysis. *Medicine (Baltimore)* **98**, e17403
788 (2019). <https://doi.org/10.1097/MD.00000000000017403>

789 78 Juhasz, G. *et al.* CNR1 gene is associated with high neuroticism and low agreeableness
790 and interacts with recent negative life events to predict current depressive symptoms.
791 *Neuropsychopharmacology* **34**, 2019-2027 (2009). <https://doi.org/10.1038/npp.2009.19>

792 79 Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H. & Astrup, A. Efficacy and
793 safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. *Lancet*
794 **370**, 1706-1713 (2007). [https://doi.org/10.1016/S0140-6736\(07\)61721-8](https://doi.org/10.1016/S0140-6736(07)61721-8)

795

796 80 Smaga, I. *et al.* Changes in the cannabinoids receptors in rats following treatment with
797 antidepressants. *Neurotoxicology* **63**, 13-20 (2017).
798 <https://doi.org/10.1016/j.neuro.2017.08.012>
799 81 Zarate, J. *et al.* Brain endocannabinoid system is involved in fluoxetine-induced
800 anorexia. *Nutr Neurosci* **11**, 111-118 (2008). <https://doi.org/10.1179/147683008X301496>
801 82 De Chiara, V. *et al.* Voluntary exercise and sucrose consumption enhance cannabinoid
802 CB1 receptor sensitivity in the striatum. *Neuropsychopharmacology* **35**, 374-387 (2010).
803 <https://doi.org/10.1038/npp.2009.141>

804

805 **Acknowledgements**

806

807 The authors thank Isabelle Labonté and Dominic Bastien from the CERVO FACS core, Marie-
808 Eve Paquet and Marc Boisvert from the CERVO POM Molecular Platform, as well as the CERVO
809 Brain Research Centre housing facility staff (special thanks to Louisabelle Gagnon) for their work
810 and support. This research was supported by the Brain Canada Foundation (2019 Future Leaders
811 in Canadian Brain Research), Canadian Institutes for Health Research (CIHR, Project Grant
812 #427011 to C.M.), Fonds de recherche du Quebec – Sante (FRQS, Junior 1 Salary Award to C.M.)
813 and C.M. Sentinel North Research Chair funded by Canada First Research Excellence Fund. M.C.
814 is supported by grants from the European Research Council (ERC: Retina-Rhythm), The Irish
815 Research Council (IRC), and an SFI Centres grant supported in part by a research grant from SFI
816 under grant number 16/RC/3948 and co-funded under the European Regional Development fund
817 by FutureNeuro industry partners. K.A.D., S.E.J.P., O.L., J.B., F.N.K. and L.D.A. are supported
818 by scholarships or fellowships from CIHR, FRQS, and the Natural Sciences and Engineering
819 Research Council of Canada (NSERC). The Douglas-Bell Canada Brain Bank is funded by the
820 RQSHA (FRQ-S) and platform support grants from Brain Canada and Healthy Brain Healthy
821 Lives (Canada First Research Excellence Fund).

822

823

824 **Author Contributions**

825

826 K.A.D. and C.M. designed research, K.A.D., S.E.J.P., A.C., M.L., O.L., J.B., F.N.K., L.D.A.,
827 V.C.F., L.B.B., C.M. and N.F. performed research including behavioral experiments, stereotaxic
828 surgeries, molecular, biochemical, and morphological analysis, M.G. and M.C. provided the
829 constructs or AAVs for functional experiments. G.T. and N.M. obtained, characterized, and
830 prepared the postmortem human samples and related data. K.A.D. and C.M. analyzed the data and
831 wrote the manuscript which was edited by all authors.

832

833 **Author Information**

834 ¹Department of Psychiatry and Neuroscience, Faculty of Medicine and CERVO Brain Research
835 Center, Université Laval, Quebec City, Canada

836 ²Faculty of Medicine and Quebec Heart and Lung Institute, Université Laval, Quebec City, Canada

837 ³Department of Biochemistry and Molecular Biology, Complutense University of Madrid, Spain

838 ⁴Smurfit Institute of Genetics, Trinity College Dublin, Lincoln Place Gate, Dublin 2 (Ireland)

839 ⁵Department of Psychiatry, McGill University and Douglas Mental Health University Institute,

840 Montreal, QC, Canada
841 ⁶Faculty of Agricultural and Food Sciences and the Faculty of Medicine, Quebec Heart and Lung
842 Institute, Université Laval, Quebec City, Canada and Institute of Biomolecular Chemistry of the
843 National Research Council, Naples, Italy
844

845

846 **Corresponding author**

847

848 *Caroline Menard, PhD, CERVO Brain Research Center, Department of Psychiatry and
849 Neuroscience, Faculty of Medicine, Université Laval, 2601 de la Canardiere, Quebec City, QC,
850 Canada, G2J 2G3, caroline.menard@fmed.ulaval.ca

851

852

853 **Keywords:** astrocyte end-feet, neurovasculature, stress adaptation, perivascular Cnr1, depression

854

855

856 **Ethics Declaration**

857

858 The authors declare no competing financial or non-financial interests.

859

860

861 **Data availability**

862

863 All data supporting the findings of this study are available within the paper and Supplementary
864 Information files.

865

866

867

868 Number of pages: 27

869 Number of figures: 7 (+7 Supplementary Figures)

870 Number of tables: 0 (+4 Supplementary Tables)

871 Number of words: 150 for the Abstract, 4,640 for the Main text

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [0MethodsFINAL.pdf](#)
- [0DudeketalSuppStatisticstable.xlsx](#)
- [0SupplementaryFiguresTablesFINAL.pdf](#)